Genmab — September 2025
-
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff https://seekingalpha.com/article/4822562-genmab-epkinly-spectacular-data-antidote-to-darzalex-patent-cliff
-
Genmab: A Matter Of Time https://seekingalpha.com/article/4822275-genmab-a-matter-of-time
-
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy https://seekingalpha.com/article/4822798-genmab-transitioning-to-a-global-oncology-powerhouse-why-i-choose-to-buy
-
Godmorgen

-
Det må være forventeligt noget fejler - Håbet må så leve videre i resten. Men alt andet lige har Genmab altså betalt for en pakke til $1,8mia, hvor GEN1107 til behandling af fremskredne solide tumorer i fase 1/2 var en del af denne pakke, der nu har vist sig at have værdien = 0
-
Genmab takes its Profound buy into endometrial
16 September 2025 https://www.oncologypipeline.com/apexonco/genmab-takes-its-profound-buy-endometrial
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind